Atossa Therapeutics, Inc. (ATOS)
Upgrades & Downgrades
Latest ATOS news
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
18 September 2023
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unme...
Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higher
8 September 2023
Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on their belief that positive trial data readouts for A...
Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen
23 August 2023
Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, a drug that combines estrogen receptor degradation...
Atossa Therapeutics, Inc. (ATOS) Q2 2023 Earnings Call Transcript
14 August 2023
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q2 2023 Earnings Conference Call August 14, 2023 9:00 AM ET Company Participants Eric Van Zanten - Vice President of Investor and Public Relations Steven Quay ...
Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansion
14 August 2023
Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled its second quarter financial results highlighted by a strong balance sheet to support the company in completing its Phase 2 trials for (Z)-endoxifen. The...
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on A...
8 August 2023
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in ca...
Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canada
20 July 2023
Atossa Therapeutics Inc (NASDAQ:ATOS) has received what's known as a no objection letter from Health Canada in response to its clinical trial application, the company announced. This means the compan...
Maxim upbeat on Atossa Therapeutics after recent updates
11 July 2023
Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enrollment update for its ongoing P2 KarismaEndoxifen stu...
Atossa Therapeutics provides update on Phase 2 breast density trial enrollment
10 July 2023
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral formulation of (Z)-endoxifen in premenopausal women ...